Sign up Australia
Proactive Investors - Run By Investors For Investors

Aphria stays a buy as Dundee Capital awaits spoils of CWP deal

Aphria Inc, the Canadian licensed marijuana producer, remained a BUY with a target price of C$1.90 per share, according to brokers at Dundee Capital Markets on Thursday.
Aphria stays a buy as Dundee Capital awaits spoils of CWP deal
Marijuana growth

Aphria Inc (CVE:APH), the Canadian licensed marijuana producer, remained a BUY with a target price of C$1.90 per share, according to brokers at Dundee Capital Markets on Thursday.

Despite the suggested underlying earnings (EBITDA) impact of the CannWay Pharmaceuticals takeover of C$0.9million this year rising to C$3.6mln in fiscal 2017, the broker said it was sitting pat awaiting the benefits of the all-share acquisition before adjusting estimates.

“We continue to apply a 10 times 2017E EV/EBITDA multiple to our C$9.4m estimate,” Dundee analyst Aaron Salz said in a note. EV, or enterprise value, is effectively the market value of the company adjusted for debt and cash.

The not-for-profit CWP has a significant market share in the veterans market, such as strong ties to the Marijuana For Trauma (MFT) community, where Aphria stands to see earnings gains.

Aphria struck an operating agreement with CWP in mid-2015 before the takeover was announced.

The takeover deal itself augments Aphria’s relationship with veterans, one of the most coveted patient groups, and takes out the “middle man” as Dundee called it, of the 2015 agreement.

Half of the 3.6 million shares are held in escrow, ensuring that the MFT community and CWP continue to be motivated in passing across new patients, and the deal ensures that for-profit Aphria can further its strategy.

Aphria shares traded one cent higher at C$1.22 on Friday.

View full APH profile View Profile

Aphria Timeline

Related Articles

Oncoprex
Thu
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use